Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GZMB | P10144 | 3/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 8/20 | 0.36 |
| ▸ | REN | P00797 | 5/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19182560 | 1.00 | GZMB (0.42) | GZMBCXCR3RENHDAC3HDAC4 | |
| SCHEMBL19181274 | 1.00 | GZMB (0.42) | GZMBCXCR3RENHDAC3HDAC4 | |
| SCHEMBL19180871 | 0.96 | GZMB (0.43) | GZMBCXCR3RENHDAC3HDAC4 | |
| SCHEMBL19180870 | 0.96 | GZMB (0.43) | GZMBCXCR3RENHDAC3HDAC4 | |
| SCHEMBL19181977 | 0.93 | GZMB (0.44) | GZMBRENHDAC3HDAC4HDAC1 | |
| SCHEMBL19182048 | 0.93 | GZMB (0.44) | GZMBRENHDAC3HDAC4HDAC1 | |
| SCHEMBL19181976 | 0.93 | GZMB (0.44) | GZMBRENHDAC3HDAC4HDAC1 | |
| SCHEMBL19181372 | 0.92 | CXCR3 (0.39) | CXCR3PTPN1 | |
| SCHEMBL19181373 | 0.92 | CXCR3 (0.39) | CXCR3PTPN1 | |
| SCHEMBL17491009 | 0.91 | GZMB (0.45) | GZMB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062803-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2020-02-27 | — | — | US | disclosed |
| US-10246487-B2 | Azaindoline compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2019-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246487-B2 | Azaindoline compounds as granzyme B inhibitors | GZMB, DNASE1L3, DNASE1 | GZMB 1/4885CXCR3 535/4885REN 3094/4885 |
| US-20200062803-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, DNASE1L3, DNASE1 | GZMB 1/4885CXCR3 535/4885REN 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.